Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
About this item
Full title
Author / Creator
Wechsler, Michael E , Akuthota, Praveen , Jayne, David , Khoury, Paneez , Klion, Amy , Langford, Carol A , Merkel, Peter A , Moosig, Frank , Specks, Ulrich , Cid, Maria C , Luqmani, Raashid , Brown, Judith , Mallett, Stephen , Philipson, Richard , Yancey, Steve W , Steinfeld, Jonathan , Weller, Peter F , Gleich, Gerald J and EGPA Mepolizumab Study Team
Publisher
United States: Massachusetts Medical Society
Journal title
Language
English
Formats
Publication information
Publisher
United States: Massachusetts Medical Society
Subjects
More information
Scope and Contents
Contents
Among participants with eosinophilic granulomatosis with polyangiitis, 32% had remission at weeks 36 and 48 when treated with mepolizumab, an anti–interleukin-5 monoclonal antibody, as compared with 3% of the participants in the placebo group.
Eosinophilic granulomatosis with polyangiitis (formerly known as the Churg–Strauss syndrome) is charact...
Alternative Titles
Full title
Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis
Authors, Artists and Contributors
Author / Creator
Akuthota, Praveen
Jayne, David
Khoury, Paneez
Klion, Amy
Langford, Carol A
Merkel, Peter A
Moosig, Frank
Specks, Ulrich
Cid, Maria C
Luqmani, Raashid
Brown, Judith
Mallett, Stephen
Philipson, Richard
Yancey, Steve W
Steinfeld, Jonathan
Weller, Peter F
Gleich, Gerald J
EGPA Mepolizumab Study Team
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5548295
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5548295
Other Identifiers
ISSN
0028-4793
E-ISSN
1533-4406
DOI
10.1056/NEJMoa1702079
